U.S. Markets open in 1 hr 40 mins
  • S&P Futures

    4,453.00
    -21.75 (-0.49%)
     
  • Dow Futures

    34,535.00
    -81.00 (-0.23%)
     
  • Nasdaq Futures

    14,714.50
    -126.50 (-0.85%)
     
  • Russell 2000 Futures

    2,017.40
    -3.80 (-0.19%)
     
  • Crude Oil

    84.42
    -1.13 (-1.32%)
     
  • Gold

    1,835.30
    -7.30 (-0.40%)
     
  • Silver

    24.45
    -0.27 (-1.08%)
     
  • EUR/USD

    1.1347
    +0.0030 (+0.2610%)
     
  • 10-Yr Bond

    1.8330
    0.0000 (0.00%)
     
  • Vix

    26.84
    +2.99 (+12.54%)
     
  • GBP/USD

    1.3573
    -0.0027 (-0.2009%)
     
  • USD/JPY

    113.7460
    -0.3540 (-0.3103%)
     
  • BTC-USD

    38,127.28
    -3,864.39 (-9.20%)
     
  • CMC Crypto 200

    893.91
    -101.36 (-10.18%)
     
  • FTSE 100

    7,500.68
    -84.33 (-1.11%)
     
  • Nikkei 225

    27,522.26
    -250.64 (-0.90%)
     

Inspira Technologies Signs a Strategic Agreement With Waas Group

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • IINN

By Sam Boughedda

Investing.com — Medical device maker Inspira Technologies Oxy BHN Ltd (NASDAQ:IINN) announced Tuesday that it has signed an exclusive distribution agreement with Anita Técnica S.L. (WAAS Group).

WAAS Group is a distributor and technical service provider of medical equipment and supplies in Spain.

The news sent Inspira shares flying over 200%, to $7.50 -- an all time high for the stock since its initial public offering in July.

The agreement has an initial seven-year term and will see the companies collaborate on the marketing and deployment of the ART device, a respiratory support system designed to treat deteriorating respiratory failure patients while they are awake and breathing.

Inspira said the device has the potential to reduce the need for mechanical ventilation across Spain and Portugal.

As part of the deal, WAAS Group is committed to purchasing a minimum of 1040 ART devices and 35,360 disposable units within seven years.

"Portugal and Spain are important markets in Europe that have extensive experience operating extracorporeal technologies. We see this as an advantage in ensuring the rapid penetration and adoption of our innovative ART device by the local medical community," said Joe Hayon, Inspira Technologies' Co-Founder, President and Chief Financial Officer.

Related Articles

Inspira Technologies Signs a Strategic Agreement With Waas Group

Airbus fends off growing revolt over jet output plans

Is Energous Corp. a Good Penny Stock to Buy?